Balchem Co. (NASDAQ:BCPC - Free Report) - Investment analysts at HC Wainwright raised their FY2024 earnings per share estimates for shares of Balchem in a research note issued to investors on Monday, November 4th. HC Wainwright analyst R. Selvaraju now forecasts that the basic materials company will post earnings of $4.01 per share for the year, up from their previous forecast of $3.81. HC Wainwright currently has a "Buy" rating and a $190.00 target price on the stock. The consensus estimate for Balchem's current full-year earnings is $4.09 per share. HC Wainwright also issued estimates for Balchem's Q4 2024 earnings at $1.10 EPS, Q1 2025 earnings at $1.06 EPS, Q2 2025 earnings at $1.09 EPS, Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.19 EPS and FY2025 earnings at $4.47 EPS.
Separately, StockNews.com raised Balchem from a "hold" rating to a "buy" rating in a report on Monday, October 28th.
View Our Latest Stock Analysis on BCPC
Balchem Price Performance
BCPC traded up $8.10 during midday trading on Wednesday, reaching $183.41. 241,999 shares of the company's stock were exchanged, compared to its average volume of 108,505. Balchem has a 1-year low of $116.84 and a 1-year high of $186.03. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.98 and a quick ratio of 1.90. The business's 50-day moving average price is $171.75 and its 200 day moving average price is $163.64. The stock has a market capitalization of $5.96 billion, a PE ratio of 47.13, a P/E/G ratio of 5.25 and a beta of 0.65.
Hedge Funds Weigh In On Balchem
Institutional investors have recently modified their holdings of the company. nVerses Capital LLC purchased a new stake in Balchem in the 3rd quarter worth approximately $35,000. Bessemer Group Inc. boosted its holdings in shares of Balchem by 568.9% during the first quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company's stock worth $47,000 after purchasing an additional 256 shares during the last quarter. Blue Trust Inc. increased its stake in Balchem by 642.5% in the third quarter. Blue Trust Inc. now owns 839 shares of the basic materials company's stock valued at $148,000 after purchasing an additional 726 shares during the last quarter. GAMMA Investing LLC lifted its position in Balchem by 73.4% during the third quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company's stock worth $148,000 after buying an additional 356 shares during the period. Finally, Private Advisor Group LLC purchased a new position in Balchem during the third quarter worth about $220,000. Institutional investors and hedge funds own 87.91% of the company's stock.
Balchem Company Profile
(
Get Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Further Reading
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
